New minimally invasive device may soon replace endoscopy for Barrett's esophagus diagnosis
the ONA take:
According to a new study published in the journal PLOS Medicine, reseearchers from the University of Cambridge MRC Cancer Unit in Cambridge, United Kingdom, have found that a new minimally invasive test can be used to identify patients with reflux symptoms to diagnose Barrett's esophagus rather than be referred for endoscopy for diagnosis.
For the study, researchers sought to evaluate the accuracy, safety, and acceptability of the test compared with endoscopy for the diagnosis of Barrett's esophagus, a disorder characterized by an abnormal change in the cells of the lower part of the esophagus that is a risk factor for the development of esophageal cancer.
Researchers enrolled 1,110 patients from various hospitals in the United Kingdom who were referred for a diagnostic endoscopy for symptoms of dyspepsia and reflux symptoms.
Results showed that the new minimally invasive test accurately diagnosed 79.7% of the 647 patients with endoscopically diagnosed Barrett's esophagus, and correctly identified 92.4% of 463 of those unaffected by Barrett's esophagus as not having Barrett's esophagus.
Researchers found that the test had an 87.2% sensitivity when patients had a circumferential Barrett's segments over 3cm. Most patients were able to swallow the device without issues and no adverse events were observed.
A new minimally invasive test can be used to identify patients with reflux symptoms to diagnose Barrett's esophagus.
Sign Up for Free e-newsletters
- Avoiding the ED: Planned Strategies for Unplanned Urgent Cancer Care
- NP-Led Clinics Improved Phase 1 Oncology Study Operations, Outcomes
- Art as Palliative Care: Bedside Intervention Improves Pain, Anxiety, Mood in Hospitalized Cancer Patients
- Unprotected Sex After Chemotherapy
- Mindfulness Training May Improve End-of-Life Conversations in Advanced Cancer
- Aligning Patient Goals With End of Life Treatment Decisions
- Study Suggests Greater Focus on the Needs of Family Caregivers of Patients With Cancer
- First Antibody-Based Treatment Regimen Approved for First-Line Treatment of Multiple Myeloma
- Increased Diabetes Risk Associated With Cancer Development
- Childhood Neuroblastoma Survivors at Risk for Psych Impairment
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|